Tags : Atypical Hemolytic Uremic Syndrome

Alexion’s Ultomiris (ravulizumab) Receives EC’s Approval for Atypical Hemolytic Uremic

Tuba Khan June 29, 2020

Shots: The EC approval is based on two ongoing studies (one in adults & other in children) assessing Ultomiris in patients with aHUS. A total of 18/21 & 56/58 complement […]readmore

Biotech

Alexion Reports Results of Ultomiris (ravulizumab-cwvz) in P-III Study in

Vartika Singh January 29, 2019

Shots: The P-III study involves assessing of Ultomiris (IV) in complement inhibitor-naïve patients with aHUS, receiving dose based on their weight varying upto 3,600 mg for 2 years P-III study […]readmore

Tags : Atypical Hemolytic Uremic Syndrome

Alexion’s Ultomiris (ravulizumab) Receives EC’s Approval for Atypical Hemolytic Uremic

Alexion Reports Results of Ultomiris (ravulizumab-cwvz) in P-III Study in

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Atypical Hemolytic Uremic Syndrome

Alexion’s Ultomiris (ravulizumab) Receives EC’s Approval for Atypical Hemolytic Uremic

Alexion Reports Results of Ultomiris (ravulizumab-cwvz) in P-III Study in

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company